MINI REVIEW article
Front. Allergy
Sec. Rhinology
Advance in biologics for chronic rhinosinusitis with nasal polyps
Yiming Di 1,2
Ruizhi Zeng 2
Lei Huang 1
Yong Wu 2
Qingwu Wu 1
1. Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
2. Sun Yat-sen University Zhongshan School of Medicine, Guangzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Abstract
Managing chronic rhinosinusitis with nasal polyps (CRSwNP) poses challenges, especially when conventional treatments fail to achieve adequate symptom control. CRSwNP is often marked by type 2 inflammation, and a large number of patients have other comorbid type 2 conditions, such as asthma. Currently, 4 biologics have been approved to treat CRSwNP—dupilumab, omalizumab, mepolizumab, and stapokibart (stapokibart is approved in China but not by the US Food and Drug Administration)—with additional promising therapies currently under development. Biologics can enhance the quality of life for CRSwNP patients, reduce the need for systemic corticosteroid therapy and endoscopic sinus surgery (ESS), and improve the management of comorbid conditions. We review clinical trials and real-world data on the effectiveness and safety of biologics for CRSwNP, compare biologic therapy and ESS, and explore the switching and simultaneous use of biologics.
Summary
Keywords
biologics, chronic rhinosinusitis with nasal polyps, Drug switching, efficacy, endoscopicsinus surgery, Safety, type 2 inflammation
Received
03 December 2025
Accepted
05 February 2026
Copyright
© 2026 Di, Zeng, Huang, Wu and Wu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Qingwu Wu
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.